Total
0
Shares
Sienna Cancer Diagnostics (ASX:SDX) - Chairman, Geoff Cumming
Chairman, Geoff Cumming
Source: AnteoTech
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sienna Cancer Diagnostics (SDX) has appointed Zotal to exclusively distribute its hTERT device in Israel
  • hTERT is an in-vitro diagnostic test used to diagnose bladder cancer
  • Israel is fast becoming a targeted health care technology market that’s expected to be worth US$6.2 billion
  • Sienna and Zotal will now focus on product registration and reimbursement applications with Israel’s Department of Medical Devices, Ministry of Health
  • Siennas shares are up 5.17 per cent and are trading for 6.1 cents each

Sienna Cancer Diagnostics (SDX) has appointed Zotal as its exclusive distributor in Israel.

Under this agreement, Zotal will market and sell Sienna’s hTERT in-vitro diagnostic medical device to pathology labs. hTERT will be used to help diagnose bladder cancer.

Zotal is considered a leading distributor and provider of high-quality products for the medical and life sciences market in Israel.

Israel is fast becoming a targeted medical device market as its elderly population increases. Israel’s health care technology market is expected to be worth roughly US$6.2 billion.

In 2018 alone, Israel recorded around 1200 new cases of bladder cancer, which provides Sienna with an opportune market to offer its diagnostic device.

“The public healthcare market is constantly seeking simple and more accurate diagnostic tools to increase the sensitivity and early detection of urothelial carcinoma as a first line diagnosis. We see the hTERT test fitting this profile perfectly,” Zotal CEO Dr Tal Zohar said.

“We are excited to partner with Sienna in Israel and anticipate a unique opportunity for the hTERT biomarker in routine care, assisting pathologists and urologists in the diagnosis of bladder cancer,” Zotal Head of Personalised and Predictive Medicine Dana Cohen said.

Sienna and Zotal will now focus on the product registration and reimbursement applications with the Department of Medical Devices, Ministry of Health in Israel. This process is expected to take approximately six months.

Sienna will provide Zotal’s staff members with sales, marketing, and technical training, while Zotal will source several reference labs to assist in the adoption of the hTERT test in Israel.

Siennas shares are up 5.17 per cent and are trading for 6.1 cents each at 12:49 pm AEST.

SDX by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.